

## Molecular Diagnostics Testing: Change to Performing Laboratory

Date: January 4, 2021

Effective Date: January 6, 2021

To allow focus on expansion of our test menu, updating assays onto the newest platforms, and improving turn-around times, the Molecular Diagnostic Laboratory will be sending out some low volume assays to a Reference Laboratory.

The tests impacted include: TERT Promoter Mutation [TERT], CEBPA Mutation Detection [CEBPA], MYD88 L265P Mutation Analysis [MYD88 (with reflex to CXCR4)] and Restricted Laboratory Permit assays: STAT3 and BTK PLCG2.

Current Test Mnemonic	Reference Lab	New Test Mnemonic	Description	Includes
N/A – Misc STAT3	Neogenomics	N/A	Identifying STAT3 mutations can help to differentiate large granular lymphocytic leukemia from reactive processes.	All coding exons of STAT3
TERTP	Mayo Clinic Laboratories	TERT	Assists in central nervous system tumor classification and prognosis.	TERT Promoter
CEBPN	Mayo Clinic Laboratories	N/A	Initial evaluation of acute myeloid leukemia, both for assigning an appropriate diagnostic subclassification and as an aid for determining prognosis.	CEBPA
MYD88	Mayo Clinic Laboratories	LPLFX	Establishing the diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM)	If a MYD88 L265P variant is detected, additional CXCR4 testing will be performed. If a MYD88 L265P variant is not detected, the algorithm ends and no further testing is necessary.

From: Zoltan Oltvai, M.D.  
 Director of the Molecular Diagnostic Laboratory  
 UR Medicine Labs  
 Phone: 585-273-2229  
 Email: Zoltan\_Oltvai@urmc.rochester.edu